 Metabolism
|
|
Genetic Information Processing
|
|
Environmental Information Processing
|
|
Cellular Processes
|
|
Organismal Systems
|
|
 Human Diseases
|
Cancer: overview
|
 05200 Pathways in cancer
05202 Transcriptional misregulation in cancer
05206 MicroRNAs in cancer
05205 Proteoglycans in cancer
05204 Chemical carcinogenesis - DNA adducts
05207 Chemical carcinogenesis - receptor activation
05208 Chemical carcinogenesis - reactive oxygen species
05203 Viral carcinogenesis
05230 Central carbon metabolism in cancer
05231 Choline metabolism in cancer
05235 PD-L1 expression and PD-1 checkpoint pathway in cancer
|
Cancer: specific types
|
05210 Colorectal cancer
05212 Pancreatic cancer
05225 Hepatocellular carcinoma
05226 Gastric cancer
05214 Glioma
05216 Thyroid cancer
05221 Acute myeloid leukemia
05220 Chronic myeloid leukemia
05217 Basal cell carcinoma
05218 Melanoma
05211 Renal cell carcinoma
05219 Bladder cancer
05215 Prostate cancer
05213 Endometrial cancer
05224 Breast cancer
05222 Small cell lung cancer
05223 Non-small cell lung cancer
|
Infectious disease: viral
|
05166 Human T-cell leukemia virus 1 infection
05170 Human immunodeficiency virus 1 infection
05161 Hepatitis B
05160 Hepatitis C
05171 Coronavirus disease - COVID-19
05164 Influenza A
05162 Measles
05168 Herpes simplex virus 1 infection
05163 Human cytomegalovirus infection
05167 Kaposi sarcoma-associated herpesvirus infection
05169 Epstein-Barr virus infection
05165 Human papillomavirus infection
|
Infectious disease: bacterial
|
05110 Vibrio cholerae infection
05120 Epithelial cell signaling in Helicobacter pylori infection
05130 Pathogenic Escherichia coli infection
05132 Salmonella infection
05131 Shigellosis
05135 Yersinia infection
05133 Pertussis
05134 Legionellosis
05150 Staphylococcus aureus infection
05152 Tuberculosis
05100 Bacterial invasion of epithelial cells
|
Infectious disease: parasitic
|
05146 Amoebiasis
05144 Malaria
05145 Toxoplasmosis
05140 Leishmaniasis
05142 Chagas disease
05143 African trypanosomiasis
|
Immune disease
|
05310 Asthma
05322 Systemic lupus erythematosus
05323 Rheumatoid arthritis
05320 Autoimmune thyroid disease
05321 Inflammatory bowel disease
05330 Allograft rejection
05332 Graft-versus-host disease
05340 Primary immunodeficiency
|
Neurodegenerative disease
|
05010 Alzheimer disease
05012 Parkinson disease
05014 Amyotrophic lateral sclerosis
05016 Huntington disease
05017 Spinocerebellar ataxia
05020 Prion disease
05022 Pathways of neurodegeneration - multiple diseases
|
Substance dependence
|
05030 Cocaine addiction
05031 Amphetamine addiction
05032 Morphine addiction
05033 Nicotine addiction
05034 Alcoholism
|
Cardiovascular disease
|
05417 Lipid and atherosclerosis
05418 Fluid shear stress and atherosclerosis
05410 Hypertrophic cardiomyopathy
05412 Arrhythmogenic right ventricular cardiomyopathy
05414 Dilated cardiomyopathy
05415 Diabetic cardiomyopathy
05416 Viral myocarditis
|
Endocrine and metabolic disease
|
04930 Type II diabetes mellitus
04940 Type I diabetes mellitus
04950 Maturity onset diabetes of the young
04936 Alcoholic liver disease
04932 Non-alcoholic fatty liver disease
04931 Insulin resistance
04933 AGE-RAGE signaling pathway in diabetic complications
04934 Cushing syndrome
|
Drug resistance: antimicrobial
|
01501 beta-Lactam resistance
01502 Vancomycin resistance
01503 Cationic antimicrobial peptide (CAMP) resistance
|
Drug resistance: antineoplastic
|
01521 EGFR tyrosine kinase inhibitor resistance
01524 Platinum drug resistance
01523 Antifolate resistance
01522 Endocrine resistance
|
|
Drug Development
|
KEGG Pathway Maps